Protective effect of naringin in an experimental model of hypogonadism associated with type 1 Diabetes mellitus
Hypogonadism is a complication associated with type 1 Diabetes mellitus (DM1). Hyperglycemia and lack of insulin trigger oxidative and nitrosative stress weakening the Leydig cells, which produce testosterone. Our objective was to evaluate the effect of the flavonoid naringin (NAR) as a protector of...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/39047 |
| Aporte de: |
| Sumario: | Hypogonadism is a complication associated with type 1 Diabetes mellitus (DM1). Hyperglycemia and lack of insulin trigger oxidative and nitrosative stress weakening the Leydig cells, which produce testosterone. Our objective was to evaluate the effect of the flavonoid naringin (NAR) as a protector of Leydig cells in an experimental model of DM1.
Control male Wistar rats (C), rats treated with 60 mg streptozotocin/kg b.w. (STZ) and STZ rats treated with NAR (20, 40 or 80 mg/kg b.w., STZ+NAR) were employed. After 30 days of treatment, the rats were sacrificed and blood and testes were obtained. Blood glucose, HbA1c and serum testosterone were determined. Glutathione content (GSH) and catalase (CAT) activity were quantified in testis homogenates. In testicular sections, the expression of the inducible enzyme nitric oxide synthase (iNOS) was evaluated by immunohistochemistry and cell apoptosis by TUNEL. The results were analyzed by ANOVA/Tukey (p<0.05). The project was approved by the CICUAL from the School of Medicine, UNC (50/17).
The STZ rats exhibited increase in the serum glucose and HbA1c values. The different doses of NAR did not affect these variables. Serum testosterone levels were lower in STZ rats. NAR40 and NAR80 treatments partially prevented this decrease (C: 5.05±0.72; STZ:1.27±0.07*; STZ+NAR20:1.55±0.13*; STZ+NAR40:2.82±0.16*#; STZ+NAR80:2.56±0.36*# ng/mL, *p<0.05 vs C, #p<0.05 vs STZ and STZ+NAR20). Therefore, the chosen treatment dose was 40 mg/kg b.w. STZ rats had lower GSH content and higher CAT activity than controls. NAR normalized these parameters. The percentage of Leydig cells with positive iNOS staining was higher in diabetic rats and NAR prevented this increase (C:35.88±7.56; STZ:77.12±6.74*; STZ+NAR:28.69±8.09, *p<0.001 vs C and STZ+NAR). The number of TUNEL (+) cells was significantly increased in the STZ group. NAR treatment blocked this enhancement (C:5.83±1.13; STZ:71.07±28.36*; STZ+NAR:5.42±3.92; *p<0.05 vs C and STZ+NAR).
The results indicate that NAR prevents the cell death by apoptosis of the Leydig cells in the experimental DM1 avoiding, at least in part, the increase in the testicular oxidative and nitrosative stress. |
|---|